These receptors respond to the cannabinoids found in medical marijuana, similar to how a key opens a lock. Medical marijuana research has demonstrated its efficacy at reducing pain when used by itself or in combination with other pain-relievers. Many cases of anecdotal evidence have been reported for arthritis patients who have very successfully used medical marijuana either in conjunction with traditional therapy or alone. “Well designed controlled trials are needed to answer many of the claims made around medical cannabis,” says Dr. Mark Ware, executive director of the Canadian Consortium for the Investigation of Cannabinoids (CCIC) and a practicing pain physician at the McGill University Health Centre. “We are continually looking for options to help treat patients who do not respond to traditional pharmacotherapy. Research of this kind will start answering some important questions about dose and efficacy, use of vapourization as a delivery system in clinical practice, and hopefully will encourage other licensed producers to join in the research endeavours.” For the 4.6 million Canadians with arthritis, anti-inflammatory and analgesic medications are the only current options available for symptom management. While effective for the majority of patients, there are some cases where current medication just isn’t enough to control the pain and inflammation. “We know that many people living with arthritis actively seek alternative options for pain relief,” said Joanne Simons, chief mission officer, The Arthritis Society. “Knowing that, we are very pleased to see that a clinical trial specific to osteoarthritis of the knee has been registered with Health Canada. Clinical research is the necessary first step to get us to where we want to go: more treatment options available for the arthritis community.” About CanniMed Ltd.
For the original version including any supplementary images or video, visit http://www.newswire.ca/en/story/1359545/first-medical-marijuana-clinical-trial-registered-with-health-canada
Its about open irrigation water, DuBray said. The policy states that in accordance with the federal Controlled Substances Act of 1970, the bureau will not approve use of Reclamation facilities or water in the cultivation of marijuana. It goes on to require bureau employees to report to their superiors if Reclamation facilities or the water they supply are being used to grow marijuana. The policy statement, which expires in May 2015, does not draw a distinction between or even specifically mention irrigation districts and municipal water suppliers, but both DuBray and Mack said the water authority falls under a specific exemption for agencies that take water from a federal source and mix it with other water in non-federal facilities before delivery to customers. Though Hoover Dam is a federal facility, the authority and its member utilities own the intake pipes and treatment plants that draw water from Lake Mead and clean it up for delivery to local taps. That wasnt always the case. The federal government built the first intake pipe and treatment plant that began delivering drinking water to Las Vegas in the early 1970s, about the same time the Controlled Substances Act took effect. The water authority bought those facilities from the Bureau of Reclamation in 2001. If that hadnt happened if the bureau still owned the pipes and pumps that may soon feed Colorado River water to the valleys legal indoor marijuana farms the new policy could be a problem, Mack said. But even if the policy did apply to the water authority, its unclear just how aggressive the bureau would be in enforcing it. As DuBray put it, echoing language in the policy statement itself: Reclamation is not an enforcement agency.
For the original version including any supplementary images or video, visit http://www.reviewjournal.com/news/water-environment/no-prohibition-seen-tapping-lake-mead-water-grow-medical-pot
I feel that medical marijuana is an appropriate treatment for a lot of people that have bad responses to traditional prescription drugs, he said. I feel in the long run, and in the short term as well, its going to save on healthcare costs enormously. Moffat believes medical marijuana is a cost-effective substitution for prescription opiates that are more addicting and have more detrimental withdrawal effects in addicted patients than medical marijuana. The problem, Moffat says, is the cost of marijuana compared to the cost of insurance-covered opiates. The 30 day supply of Vicodin costs them $5 because insurance covers it, but if they wanted to get an ounce of medical marijuana thats going to cost them $400-$500, Moffat said. I dont think it makes a lot of sense that were letting what is really an appropriate treatment for a lot of folks be underutilized. Issues with Smoking as Medicine Experts against adding medical marijuana to Obamacare argue that smoking is not an acceptable means of medicating an individual. I think the chances of getting a smoked joint covered by Obamacare is zip, said Kevin Sabet, Ph.D.
For the original version including any supplementary images or video, visit http://www.golocalprov.com/politics/obamacare-implications-of-medical-marijuana-in-rhode-island/
Noreen Evans (D-Santa Rosa), now heads to the Senate Appropriations Committee. On Tuesday, Lake County medical marijuana supporters handed in signatures for an initiative that would revise the county’s cultivation policies. The Medical Marijuana Control Act would allow four marijuana plants per parcel on properties of under an acre, limit collective gardens to 48 plants on rural properties of five acres or more, require fully fenced and locked garden areas, create a medical marijuana enforcement division in the Community Development Department and establish a medical marijuana enforcement officer position. It needs 2,115 valid signatures to qualify for the November ballot; proponents handed in more than 3,000 raw signatures. Also on Tuesday, the San Jose city council punted on its dispensary ordinance . The council delayed voting on its controversial measure until next week. The decision to postpone the vote came after hours of heated and emotional testimony on all sides of the issue. Illinois On Wednesday, the House approved medical marijuana for seizures . The House approved Senate Bill 2636 , which expands the state’s medical marijuana law to include both adults and minors suffering from seizure disorders.
For the original version including any supplementary images or video, visit http://stopthedrugwar.org/chronicle/2014/may/21/medical_marijuana_update
2014s college graduates will find themselves with a potential career path that graduates just one decade ago couldnt have even imagined. Medical marijuana (and in Colorado and Washington, outright legal marijuana) is a, eh ehm, budding industry packed with more job opportunities than meets the eye. The rapid growth of the U.S. marijuana industry is generating thousands of new jobs. It is estimated that there are around 10,000 marijuana-related jobs in Colorado alone, says Dan Kingston, president of locally-based job board 420careers.com, in a press release. With MMJ and legalization slowly becoming the norm across the country, its an industry that will only expand in the coming years. Marijuana-related jobs are expected to quadruple in 2014, according to Hemp America Media Group. As an MMJ state, Arizona is a hot ground for these new career opportunities, just behind California and Colorado in number of jobs posted.
For the original version including any supplementary images or video, visit http://www.ecollegetimes.com/reach-a-career-high-with-a-job-in-medical-marijuana-1.2867766
Its really going to be a difficult policy no matter which way we go. At the April 21 meeting of the BHA, the housing authority commissioners discussed the policy. The U.S. Department of Housing and Urban Development sent a letter to all of the housing authorities in the state saying that new admissions will be prohibited from entering into the federally subsidized housing program if they are using any controlled substance, including medical marijuana. In that same letter HUD stated that it will be up to the public housing authorities to establish their own occupancy standards for existing residents, and so the BHA commissioners are trying to come up with a standard policy. At the April 21 meeting BHA Commissioner Tom Finnell said he thought it would be wrong for the housing authority to force a tenant out of an apartment, or to prevent him or her from using the medicinal marijuana. As far as new applicants go, it seems our hands are tied, but we can allow tenants to use it if they are registered users, said Finnell.
For the original version including any supplementary images or video, visit http://www.pottsmerc.com/general-news/20140522/vt-housing-authority-struggles-with-conflict-of-medical-marijuana-federal-housing-rules
It will also explore the short-term safety of vapourized cannabis as well as to look at functional changes and patient preference. Prairie Plant Systems is currently finalizing the agreements with the two main trial sites. Patient recruitment details will be announced in the coming weeks. “With 36 per cent of the patients registered in the former MMAR program suffering with symptoms of serve arthritis – the largest concentration of any disease area – we felt there was no option but to continue our clinical exploration within this important patient group,” said Brent Zettl, President and CEO of Prairie Plant Systems and CanniMed. “Today we are announcing the launch of our clinical trial program where we will formally study several varieties of medical marijuana to determine not only the safety and efficacy of pharmaceutical-grade cannabis, but also to provide prescribing physicians with the clinical data they are looking for regarding dosing.” Studies show that the body’s own pain-regulating system, (the endocannabinoid system) has receptors in nervous system tissue, immune cells, bone and joint tissue. These receptors respond to the cannabinoids found in medical marijuana, similar to how a key opens a lock. Medical marijuana research has demonstrated its efficacy at reducing pain when used by itself or in combination with other pain-relievers. Many cases of anecdotal evidence have been reported for arthritis patients who have very successfully used medical marijuana either in conjunction with traditional therapy or alone. “Well designed controlled trials are needed to answer many of the claims made around medical cannabis,” says Dr. Mark Ware, executive director of the Canadian Consortium for the Investigation of Cannabinoids (CCIC) and a practicing pain physician at the McGill University Health Centre.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/first-medical-marijuana-clinical-trial-130000981.html
Bazil, a professor of clinical neurology and director of the Division of Comprehensive Epilepsy Center and Sleep Center at Columbia University in New York, knows there are many anecdotal reports of cannabis aiding people with epilepsy, but says the studies don’t prove it. “Individuals who think that cannabis improved or cured their seizures could have improved for other reasons,” he says. According to the National Institute on Drug Abuse (NIDA), the Food and Drug Administration (FDA) has approved dronabinol (Marinol), which contains THC and is used to treat nausea caused by chemotherapy as well as wasting disease caused by AIDS. It has also approved nabilone (Cesamet), which is made of a synthetic cannabinoid similar to THC and is used to treat the same conditions. Another drug, Sativex, is being used in the United Kingdom to treat multiple sclerosis and it is now in Phase III clinical trials in the U.S. for cancer pain. Related News: Can One Pill Reduce the ‘Haze’ of Medical Marijuana Use More Information Needed Another journal article discusses scientific evidence of CBD being used to treat epilepsy and other neurological or psychiatric disorders such as anxiety, schizophrenia, and addiction. Previous studies found that THC, the primary psychoactive substance in cannabis, and CBD, the main non-psychoactive ingredient, display anticonvulsive properties in animals. But data presented in the research is limited for chronic episodesand missing entirely for human cases.
For the original version including any supplementary images or video, visit http://www.healthline.com/health-news/medical-marijuana-may-help-seizures-052214
NOTE: The Commissioner of Health will register a designated caregiver for a patient if the patients health care provider certifies that the patient is unable to self-administer medication. STEP 2: After receipt of a patients application, the Commissioner of Health will enroll the patient in the registry program and issue a registry verification. Applications will be denied only under specific circumstances, such as an applicant providing false information or an applicant lacking certification that he or she has one of the qualifying medical conditions. STEP 3: Minnesotans issued a registry verification will be eligible to receive medical cannabis for their condition at one of the distribution facilities set up by the states medical cannabis manufacturers. STEP 4: As part of their certification and participation in the program, patients must agree to continue treatment for their condition and their health care provider must agree to provide ongoing reports about the patients health status/condition. HOW WILL THE MEDICAL CANNABIS BE PROVIDED? The medical cannabis provided to patients in the registry program will come from two in-state manufacturers licensed and inspected by the state. To become registered manufacturers of medical cannabis, entities must apply to the Commissioner of Health for consideration. The Commissioner will consider multiple factors in assessing manufacturer applications including fees to be charged.
For the original version including any supplementary images or video, visit http://kstp.com/article/stories/S3439194.shtml
3 hours ago 0 shares LONGMONT, CO–(Marketwired – May 23, 2014) – MediJane Holdings Inc. ( OTCQB : MJMD ) (“MediJane” or “MJMD” or the “Company”) is pleased to announce that it has approved the final formulation as well as product branding for its new line of dissolvable oral medical cannabis “Medi-Strips.” Fast dissolving films are gaining interest as an oral delivery alternative to tablets and pills.The mint flavored Medi-Strips films are designed to dissolve upon contact with a wet surface, such as the tongue, allowing the patient to take the product without need for additional liquid.As the drug is directly absorbed into systemic circulation, degradation in gastrointestinal tract and first pass effect can be avoided.This convenience factor provides both a marketing advantage and increased patient compliance.Over-the-counter films for pain management and motion sickness have already been successfully commercialized in the US markets and mainstream consumer acceptance increases daily.Combining medical cannabis with this delivery system gives the user a discreet, controlled dose of nighttime pain relief without any oral ingestion complications that can often afflict terminal patients. “We are absolutely elated to be providing such an innovative and cutting edge delivery system for cannabinoids.Our thin film medicated strips are an orally absorbed, fast acting, dissolvable medical cannabis delivery platform that will provide patients quick and long lasting pain relief.I am also excited about the extensions into tertiary demographics, such as geriatrics where oral ingestion and choking hazards are common place.I believe this product will have mainstream, as well as, targeted appeal throughout the medical cannabis marketplace,” commented Dr. Joseph Cohen, Chief Medical Officer of MediJane Holdings. Spike Humer, Chairman of MediJane, concluded, “With all development aspects of this new product line complete, we are very eager to get MediJane Medi-Strips into customer hands quickly wherever legal medical cannabis is sold.This product launch solidifies the direction we are headed in as a company which is to provide medical cannabis to patients utilizing the most innovative, accurate, and reliable delivery systems available.” About MediJane Holdings Inc. (MJMD) MediJane Holdings Inc. (MJMD) is in the business of marketing and distributing products within the medical marijuana industry, including transdermal patches, capsules, sublingual sprays, and other medical delivery systems as part of its strategic alliances with Phoenix Bio Pharmaceuticals ( www.phoenixbiopharmaceuticals.com ).With sales offices opening in California and Colorado, and a planned expansion into a national footprint, MediJane products are designed to give doctors the ability to provide patients accurate and effective doses of cannabinoids to manage and treat pain and other specific illnesses.MediJane’s lead products, the innovative non-drowsy “Daytime Pain plus CBD” oral capsule and the Canna-Mist cannabinoid spray, have been formulated for the treatment of inflammation and chronic, neuropathic, arthritic, and back pain.These smokeless alternatives provide accurate dosages and are part of MediJane’s initial launch into the chronic pain management market, which is estimated at over $45 billion annually in North America.Any and all medically oriented statements have not been evaluated by the Food and Drug Administration. For more information, visit www.medijane.co Disclaimer/Safe Harbor: Some information in this MediJane Holdings Inc.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/medijane-holdings-finalizes-medical-cannabis-120500700.html